3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
24
Paclitaxel
7
Docetaxel
7
Cyclophosphamide
7
Carboplatin
7
fludarabine
6
Taxes
6
Nivolumab
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
atezolizumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Gemcitabine
4
Fluorouracil
4
Cisplatin
4
tisotumab vedotin
3
fludarabine phosphate
3
Radiation
3
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Gene Expression Profiling
3
Drug Therapy
3
Counseling
3
Albumin-Bound Paclitaxel
3
zimberelimab
2
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Interleukin-15
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled